Importance of in vitro conditions for modeling the in vivo dose in humans by in vitro–in vivo extrapolation (IVIVE)
- 134 Downloads
In vitro studies are increasingly proposed to replace in vivo toxicity testing of substances. We set out to apply physiologically based pharmacokinetic (PBPK) modeling to predict the in vivo dose of amiodarone that leads to the same concentration–time profile in the supernatant and the cell lysate of cultured primary human hepatic cells (PHH). A PBPK human model was constructed based on the structure and tissue distribution of amiodarone in a rat model and using physiological human parameters. The predicted concentration–time profile in plasma was in agreement with human experimental data with the unbound fraction of amiodarone in plasma crucially affecting the goodness-of-fit. Using the validated kinetic model, we subsequently described the in vitro concentration–time data of amiodarone in PHH culture. However, this could be only appropriately modeled under conditions of zero protein binding and the very low clearance of the in vitro system in PHH culture. However, these represent unphysiological conditions and, thus, the main difference between the in vivo and the in vitro systems. Our results reveal that, for meaningful quantitative extrapolation from in vitro to in vivo conditions in PBPK studies, it is essential to avoid non-intended differences between these conditions. Specifically, clearance and protein binding, as demonstrated in our analysis of amiodarone modeling, are important parameters to consider.
KeywordsPharmacokinetics Amiodarone Animal alternatives In silico Physiologically based pharmacokinetic modeling Hepatotoxicity
We would like to thank Dr. E. Di Consiglio and Dr. E. Testai, Istituto Superiore di Sanità, Environment and Primary Prevention Dept., Mechanisms of Toxicity Unit, Rome, Italy, for providing us with the concentration–time data of amiodarone in the supernatant and the human hepatic cells. We also thank Dr. Yuan-Sheng Zhao for the support with the implementation of the rat model.
- Bessems JG et al (2014) PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA–EURL ECVAM ADME workshop Regulatory. Toxicol Pharmacol 68:119–139Google Scholar
- Dan GA et al (2018) Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP) Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of. Cardiology 20:731–732. https://doi.org/10.1093/europace/eux373 anCrossRefGoogle Scholar
- Leist M, Hasiwa N, Rovida C, Daneshian M, Basketter D, Kimber I, Clewell H, Gocht T, Goldberg A, Busquet F, Rossi A-M, Schwarz M, Stephens M, Taalman R, Knudsen T, McKim J, Harris G, Pamies D, Hartung T (2014) Consensus report on the future of animal-free systemic toxicity testing. Altern Anim Exp ALTEX 31:341–356. https://doi.org/10.14573/altex.1406091 CrossRefGoogle Scholar
- Lu J-T, Cai Y, Chen F, Jia W-W, Hu Z-Y, Zhao Y-S (2016) A physiologically based pharmacokinetic model of amiodarone and its metabolite desethylamiodarone in rats: pooled analysis of published data. Eur J Drug Metab Pharmacokinet 41:689–703. https://doi.org/10.1007/s13318-015-0295-0 CrossRefPubMedGoogle Scholar
- Mielke H, Di Consiglio E, Kreutz R, Partosch F, Testai E, Gundert-Remy U (2017) The importance of protein binding for the in vitro-in vivo extrapolation (IVIVE)-example of ibuprofen, a highly protein-bound substance. Arch Toxicol 91:1663–1670. https://doi.org/10.1007/s00204-016-1863-z CrossRefPubMedGoogle Scholar
- Pridgeon CS et al (2018) Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms. Arch Toxicol 92:557–569. https://doi.org/10.1007/s00204-018-2152-9 CrossRefPubMedPubMedCentralGoogle Scholar